X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
eFT226 (zotatifin), a small molecule inhibitor of the RNA helicase eIF4A, is currently undergoing evaluation in Phase II clinical trials in combination with Fulvestrant for treating ER+ & HER2-negative Breast cancer.
Lead Product(s): Zotatifin,Fulvestrant
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2023
Details:
eFT226 (zotatifin) is a potent and sequence-selective small molecule inhibitor of the RNA helicase eIF4A. It is being evaluated in combination with fulvestrant and abemaciclib for treatment of ER+/HER2- advanced metastatic breast cancer.
Lead Product(s): Zotatifin,Fulvestrant,Abemaciclib
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
The collaboration will aims to evaluate eFT226 (zotatifin) in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a pre-operative setting.
Lead Product(s): Zotatifin,Fulvestrant
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Stanford Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 11, 2023
Details:
eFT226 (zotatifin) is a potent and sequence-selective small molecule inhibitor of eIF4A that is designed to suppress expression of a network of cancer driving proteins, including Cyclins D and E, CDKs 2, 4 and 6 and select RTKs as well as KRAS.
Lead Product(s): Zotatifin
Therapeutic Area: Infections and Infectious Diseases Product Name: eFT226
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
eFT226 (Zotatifin) is a potent and sequence-selective small molecule inhibitor of eIF4A that is designed to suppress expression of a network of cancer driving proteins, including Cyclins D and E, CDKs 2, 4 and 6 and select RTKs as well as KRAS.
Lead Product(s): Zotatifin,Fulvestrant
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
eFT226 (zotatifin) is potent and sequence-selective small molecule inhibitor of eIF4A that is designed to suppress expression of a network of cancer driving proteins, Cyclins D and E, CDKs 2, 4 and 6 and select RTKs as well as KRAS.
Lead Product(s): Zotatifin
Therapeutic Area: Infections and Infectious Diseases Product Name: eFT226
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
eFT226 (zotatifin) is a potent and sequence-selective small molecule inhibitor of eIF4A, a host protein required to unwind the complex secondary structures within the 5’ untranslated region of the genome of SARS-CoV-2 and other RNA viruses.
Lead Product(s): Zotatifin
Therapeutic Area: Infections and Infectious Diseases Product Name: eFT226
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
Positive interim results of eIF4A inhibitor eFT226 (zotatifin) in patients with solid tumors that showed treatment was generally well tolerated, resulted in suppression of multiple oncogenic drivers and demonstrated initial signals of clinical activity.
Lead Product(s): Zotatifin
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2022
Details:
Zotatifin (eFT226) is eFFECTOR’s wholly-owned potent and selective inhibitor of mRNA helicase eIF4A, designed to downregulate expression of key oncoproteins and cell cycle proteins that drive tumor growth and resistance.
Lead Product(s): Zotatifin
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor 4A (eIF4A) mediated translation used in solid tumor indications, including triple negative breast cancer.
Lead Product(s): Zotatifin
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Baylor College of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
Zotatifin, is a small molecule inhibitor of eIF4A. eIF4A is a helicase responsible for unwinding complex secondary structures in “onco” mRNAs and enables select tumor cells to overproduce proteins associated with cellular growth.
Lead Product(s): Zotatifin
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Baylor College of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
Since zotatifin inhibits the translation of mRNA in the non-coding region of mRNAs, it is not limited to specific KRAS activating mutation subtypes such as KRAS G12C or KRAS G12D.
Lead Product(s): Zotatifin
Therapeutic Area: Infections and Infectious Diseases Product Name: eFT226
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2021
Details:
Zotatifin, the company’s product candidate targeting eIF4A, downregulates key cancer-driving proteins including receptor tyrosine kinase (RTK) proteins (HER2, FGFR1, and FGFR2), as well as cell cycle protein Cyclin D1.
Lead Product(s): Zotatifin,Undisclosed
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Preclinical evaluation results of eFT226 showed that zotatifin significantly inhibited tumor growth and caused tumor regression across diverse RTK-driven tumor types.
Lead Product(s): Zotatifin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
